Hubbry Logo
Decay-accelerating factorDecay-accelerating factorMain
Open search
Decay-accelerating factor
Community hub
Decay-accelerating factor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Decay-accelerating factor
Decay-accelerating factor
Decay-accelerating factor
View on Wikipedia
from Wikipedia
CD55
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCD55, CR, CROM, DAF, TC, CD55 molecule (Cromer blood group), CHAPLE
External IDsOMIM: 125240; MGI: 104849; HomoloGene: 479; GeneCards: CD55; OMA:CD55 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1604

13137

Ensembl

ENSG00000196352

ENSMUSG00000026401

UniProt

P08174

Q61476

RefSeq (mRNA)

NM_007827
NM_001317361

RefSeq (protein)

NP_000565
NP_001108224
NP_001287831
NP_001287832
NP_001287833

NP_001304290
NP_031853
NP_001391877

Location (UCSC)Chr 1: 207.32 – 207.39 MbChr 1: 130.32 – 130.35 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Complement decay-accelerating factor, also known as CD55 or DAF, is a protein that, in humans, is encoded by the CD55 gene.[5]

DAF regulates the complement system on the cell surface. It recognizes C4b and C3b fragments that are created during activation of C4 (classical or lectin pathway) or C3 (alternative pathway). Interaction of DAF with cell-associated C4b of the classical and lectin pathways interferes with the conversion of C2 to C2b, thereby preventing formation of the C4b2a C3-convertase, and interaction of DAF with C3b of the alternative pathway interferes with the conversion of factor B to Bb by factor D, thereby preventing formation of the C3bBb C3 convertase of the alternative pathway. Thus, by limiting the amplification convertases of the complement cascade, DAF indirectly blocks the formation of the membrane attack complex.[6]

This glycoprotein is broadly distributed among hematopoietic and non-hematopoietic cells. It is a determinant for the Cromer blood group system.

Structure

[edit]

DAF is a 70 kDa membrane protein that attaches to the cell membrane via a glycophosphatidylinositol (GPI) anchor.

DAF contains four complement control protein (CCP) repeats with a single N-linked glycan positioned between CCP1 and CCP2. CCP2, CCP3, CCP4 and three consecutive lysine residues in a positively charged pocket between CCP2 and CCP3 are involved in its inhibition of the alternate complement pathway. CCP2 and CCP3 alone are involved in its inhibition of the classical pathway.[7]

Pathology

[edit]

Paroxysmal nocturnal hemoglobinuria

[edit]

Because DAF is a GPI-anchored protein, its expression is reduced in persons with mutations that reduce GPI levels such as those with paroxysmal nocturnal hemoglobinuria (PNH). In PNH disorder, red blood cells with very low levels of DAF and CD59 undergo complement-mediated hemolysis. Symptoms include low red blood cell count (anemia), fatigue, and episodes of dark colored urine and other complications.[8]

Infectious diseases

[edit]

DAF is used as a receptor by some coxsackieviruses and other enteroviruses.[9] Recombinant soluble DAF-Fc has been tested in mice as an anti-enterovirus therapy for heart damage;[10] however, the human enterovirus that was tested binds much more strongly to human DAF than to mouse or rat DAF. Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF.[11] and DAF-Fc has yet to be tested in humans.

Binding of DAF to human HIV-1 when the virons are budding from the surface of infected cells protects HIV-1 from complement mediated lysis.[12][13]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Decay-accelerating factor

View on Grokipedia
from Grokipedia
Decay-accelerating factor (DAF), also known as CD55, is a (GPI)-anchored membrane that functions as a primary regulator of the by accelerating the decay of C3 and C5 convertases in both the classical and alternative pathways, thereby preventing the formation of the membrane attack complex and protecting host cells from autologous complement-mediated lysis. Discovered in 1969 by E.M. Hoffmann, who isolated it from erythrocytes as a heat-stable factor inhibiting complement activity, DAF is encoded by the CD55 gene on chromosome 1q32 and exists in both membrane-bound and soluble forms. Structurally, DAF consists of four complement control protein (CCP) modules, also known as short consensus repeats (SCRs), each approximately 60 long, connected by short linkers and suspended above the by a serine//proline-rich region and a GPI anchor. The protein's molecular weight ranges from 50 to 100 kDa due to , extensive O- in the stalk region, and a single N-linked glycan at 61 between CCPs 1 and 2, though this glycosylation is not essential for its regulatory function. CCPs 2 and 3 are primarily responsible for binding and dissociating the classical pathway (C4b2a), while CCPs 2, 3, and 4 mediate activity against the alternative pathway convertase (C3bBb); key residues such as the hydrophobic leucine-phenylalanine pair (L147F148) in CCP3 and the positively charged cluster (KKK125–127) between CCPs 2 and 3 are critical for these interactions. DAF is broadly expressed on the surface of most human cells, including erythrocytes, leukocytes, endothelial and epithelial cells, as well as in soluble forms in plasma, , , , and , ensuring widespread protection against inadvertent complement activation. Beyond complement regulation, DAF modulates innate and adaptive immunity by suppressing T-cell and natural killer (NK) cell activity through interactions with and serves as a for the adhesion CD97, influencing and signaling. It also acts as a receptor for pathogens, notably facilitating invasion by Plasmodium falciparum in , where CD55-null erythrocytes show resistance to infection. In disease contexts, DAF deficiency underlies conditions like (PNH), characterized by GPI-anchor defects leading to increased complement-mediated , and complement hyperactivation-associated protein-losing enteropathy (CHAPLE), resulting in gastrointestinal symptoms and due to unchecked complement activity; CHAPLE is treated with pozelimab (Veopoz), approved by the FDA in 2023 as the first specific therapy. Conversely, DAF is frequently overexpressed in various malignancies, including colorectal, , ovarian, and cancers, promoting tumor immune evasion and progression, which has positioned it as a potential therapeutic target for complement-enhancing anticancer strategies. Additionally, DAF contributes to autoimmune disorders such as and via CD55-CD97 interactions that exacerbate inflammation.

Molecular structure

Protein domains

The decay-accelerating factor (), also known as CD55, is a composed of 381 in its precursor form, including an N-terminal of 34 that directs translocation to the and a C-terminal (GPI) signal sequence of approximately 28 that facilitates membrane anchoring. The mature extracellular domain spans 319 , comprising four complement control protein (CCP) domains, also termed short consensus repeats (SCR), followed by a serine/threonine-rich stalk region rich in sites. Each of the four CCP domains (CCP1–CCP4) consists of approximately 60 and exhibits a conserved modular architecture typical of the regulators of complement activation (RCA) family. These domains feature two intramolecular bonds formed by four conserved residues, which stabilize a compact β-barrel-like fold comprising up to eight antiparallel β-strands arranged in a hydrophobic core, often anchored by a conserved residue. The β-sheet structure creates concave and convex faces, with the concave face implicated in interactions, while flexible loops and turns account for about half of each domain's residues, contributing to functional adaptability. The CCP domains play distinct yet cooperative roles in DAF's complement regulatory function, primarily by binding to C3b and C4b fragments to accelerate the decay of C3 and C5 convertases. CCP2 and CCP3 form the core for C3b and C4b, with CCP2 containing a positively charged region (residues 125–127) essential for alternative pathway regulation and CCP3 featuring a hydrophobic pocket (residues 147–148) critical for decay acceleration in both classical and alternative pathways. CCP1 primarily contributes to structural stabilization and positioning of the , while CCP4 enhances activity specifically in the alternative pathway by supporting the dissociation of Bb from C3bBb convertases, requiring all three CCP2–CCP4 for full efficacy. Structural studies, including (NMR) spectroscopy of the CCP2–CCP3 fragment and of DAF in complex with 7, reveal an extended, rod-like arrangement of the domains with significant inter-domain flexibility at linker regions, allowing hinge-like adjustments (tilt angles of 35–39°) to accommodate binding without rigid inter-module contacts. This flexibility, evidenced by residual dipolar couplings in NMR data, enables the concave faces of adjacent CCPs to align optimally for multivalent interactions with convertase surfaces, underscoring the modular design's role in efficient complement inhibition.

Anchoring and modifications

The decay-accelerating factor (), also known as CD55, is anchored to the via a () anchor, which lacks a and allows flexible lateral movement within the . The anchor consists of a moiety linked through a conserved glycan core—comprising a , three mannoses, and a phosphoethanolamine bridge—to the C-terminal serine residue of the mature protein following proteolytic cleavage of the C-terminal signal sequence. This ethanolamine-linked structure integrates into the outer leaflet of the plasma membrane, facilitating its role in surface protection without intracellular signaling domains. A prominent feature of DAF is extensive in its serine/threonine-rich stalk region, spanning approximately amino acids 261 to 319, which contains 14–16 O-linked oligosaccharide chains primarily composed of GalNAc-based mucin-type structures. These modifications add approximately 20 kDa to the protein's mass and serve a protective function by shielding the stalk from attack, thereby enhancing DAF stability on the cell surface. In contrast, N-linked is limited to a single site at 61 within the first complement control protein (CCP1) domain, featuring a complex biantennary glycan that contributes to proper folding and solubility but accounts for only a minor portion of the total carbohydrate content. The overall post-translational modifications result in an apparent molecular weight of ~70 for membrane-bound DAF on , substantially higher than the predicted 41 from its sequence due to the combined ~30 from glycans. Variations in GPI anchor density across cell types or under pathological conditions can modulate DAF's surface mobility, with higher densities promoting nanoclustering in lipid rafts and improved diffusion to complement activation sites, while lower densities may reduce functional efficiency.

Genetics and expression

CD55 gene

The CD55 gene, which encodes the decay-accelerating factor (DAF) protein, is located on the long arm of chromosome 1 at the q32.2 cytogenetic band. It spans approximately 40 kb of genomic DNA and comprises 14 exons, as determined by detailed genomic analysis. This organization places CD55 within a chromosomal locus that also harbors other genes encoding complement regulatory proteins, facilitating coordinated regulation of complement pathways. The exon-intron structure of CD55 reflects the modular architecture of the DAF protein. Exon 1 encodes the N-terminal responsible for directing the nascent polypeptide to the secretory pathway. Exons 2 through 5 each encode one of the four complement control protein (CCP) domains (CCP1–CCP4), which are short consensus repeats critical for ligand binding. Exon 6 encodes the serine/threonine-rich stalk region that provides flexibility to the extracellular domain. Finally, exons 7–9 encode the (GPI) anchor attachment signal, enabling membrane anchoring of the mature protein, while in later exons can generate soluble isoforms lacking the GPI moiety. This exon arrangement supports diverse transcript variants, with at least 10 protein-coding isoforms identified. Polymorphisms in the CD55 gene primarily affect the blood group system (CROM), a collection of 16 antigens expressed on erythrocytes and other cells via . These antigens arise from single polymorphisms (SNPs), predominantly in the exons encoding CCP domains, altering recognition without disrupting overall protein function in most cases. For instance, the rare Inab phenotype, characterized by complete absence of all Cromer antigens and reduced DAF expression, results from homozygous or frameshift , such as the W53X in 2 (c.159G>A), leading to premature termination and negligible protein production. Other Cromer variants, like Dr(a–), stem from missense such as S165L in 5, which impair antigen expression but retain partial DAF activity. These genetic variants are recessive and have been mapped through family studies and sequencing of affected individuals. Transcriptional regulation of CD55 is responsive to inflammatory signals, particularly cytokines involved in immune . The gene's promoter region contains elements that mediate upregulation in response to interferon-gamma (IFN-γ), a key proinflammatory produced during and . In cell types such as colonic epithelial cells and certain tumor lines, IFN-γ treatment increases CD55 mRNA and surface protein levels, enhancing complement protection under stress conditions. This -inducible expression helps modulate local immune responses by bolstering membrane complement regulators on host cells. Additional cytokines like tumor necrosis factor-alpha (TNF-α) can synergize or antagonize this effect depending on the cellular context, underscoring CD55's role in adaptive immune .00290-1)

Tissue distribution

Decay-accelerating factor (), also known as CD55, exhibits ubiquitous expression across human cell types, serving as a key membrane-bound regulator of complement activation on the cell surface. It is prominently present on hematopoietic cells, including erythrocytes, leukocytes such as monocytes and granulocytes, and other blood cells, where it protects against autologous complement-mediated lysis. In non-hematopoietic lineages, is widely distributed on cells routinely exposed to complement, notably endothelial and epithelial cells lining vascular and mucosal surfaces. This broad localization underscores its role in safeguarding diverse tissues from inadvertent immune damage. Particularly high levels of DAF expression are observed on vascular , where it contributes to the integrity of walls amid constant complement exposure, and in the , especially at the feto-maternal interface on extravillous trophoblasts throughout . In contrast, neuronal cells display relatively low constitutive DAF expression, though it can be induced in response to inflammatory or stress signals, such as hypoxia-reoxygenation. During erythroid development, DAF expression on erythrocytes diminishes as cells mature, reflecting a shift in profiles post-differentiation. DAF expression is dynamically regulated, with upregulation occurring in response to inflammatory stimuli via transcription factors like , as seen in cytokine-activated endothelial and immune cells. Additionally, a soluble isoform (sDAF) is secreted from certain tissues, including epithelial linings, and circulates in plasma, , , , and , potentially extending complement inhibitory functions beyond cell surfaces.

Biological function

Complement regulation

The decay-accelerating factor (), also known as CD55, serves as a key membrane-bound regulator of the by inhibiting the activation of the classical and alternative pathways at the level of C3 and C5 convertases. DAF binds directly to the C3b and C4b components of these convertases, accelerating their dissociation into inactive forms: specifically, it promotes the release of C2a from the classical pathway convertase C4b2a and Bb from the alternative pathway convertase C3bBb. This decay-accelerating activity occurs at a rate approximately 10- to 20-fold faster than spontaneous dissociation, thereby limiting the amplification of complement activation and preventing excessive deposition of C3b on host cells. By disrupting convertase stability, DAF reduces the generation of downstream effectors such as anaphylatoxins (C3a and C5a) and the membrane attack complex (MAC), protecting self-tissues from inadvertent . In addition to its decay-accelerating function, DAF acts as a cofactor for the factor I, facilitating the proteolytic cleavage of surface-bound C3b to its inactivated form iC3b and C4b to C4d. This cofactor activity further dampens complement amplification by inactivating the opsonin C3b, which would otherwise promote and further convertase assembly, while iC3b retains limited opsonic potential but cannot sustain the cascade. Unlike some regulators, DAF's dual mechanisms—decay acceleration and cofactor function—target both pathways without directly inhibiting MAC formation, making it essential for early-stage control of complement on cell surfaces. DAF exhibits species-specific activity in complement regulation, with human DAF being ineffective at inhibiting porcine complement components, a limitation that has implications for where porcine organs are at risk from human complement attack. Native porcine regulators fail to adequately control human complement, necessitating the expression of human DAF in transgenic pigs to protect grafts from hyperacute rejection. DAF functions in synergy with other complement regulators, such as , which specifically inhibits MAC assembly by binding C9 and preventing pore formation, and membrane cofactor protein (MCP or CD46), which provides cofactor activity but lacks decay-accelerating capability. This coordinated action ensures comprehensive inhibition across the complement cascade: DAF and MCP at the convertase stage, complemented by at the terminal stage.

Immune modulation

Beyond its primary function in complement inhibition, decay-accelerating factor (, also known as CD55) exerts complement-independent effects on immune cells, influencing innate and adaptive responses through cell surface interactions and signaling pathways. serves as a ligand for the CD97, which is expressed on leukocytes including monocytes, granulocytes, and activated T and B cells. This interaction functions as a costimulatory signal, enhancing T cell activation by promoting proliferation of + T cells when co-engaged with the (CD3), as demonstrated in peripheral blood studies where CD97-mediated stimulation of CD55 increased expression of activation markers such as and CD25. Furthermore, the CD55-CD97 binding facilitates leukocyte and migration, supporting T cell recruitment to inflammatory sites without interfering with 's complement regulatory activity. In innate immune modulation, DAF contributes to polarization toward an anti-inflammatory phenotype through signaling cascades independent of complement. Upregulation of DAF represses (TLR) signaling and autocrine complement receptor (C3aR1/C5aR1) activation, thereby enabling activity, cyclic AMP (cAMP) production, and (PKA)-mediated phosphorylation of CREB, which in turn supports Krüppel-like factor 4 ()-driven expression of markers like arginase-1 (Arg-1) and resistin-like alpha (Retnla). This mechanism suppresses proinflammatory M1 responses, including reduced expression of chemoattractant protein-1 (MCP-1) and inducible (iNOS), as evidenced in DAF-deficient s where polarization is impaired. Such polarization fosters a tolerogenic environment, linking DAF to resolution of inflammation. DAF also modulates adaptive signaling, particularly by regulating production in T cells. In murine models of , DAF deficiency results in hypersecretion of interleukin-2 (IL-2) by restimulated T cells, indicating that DAF normally suppresses IL-2 output to temper T cell responses; this effect is complement-dependent, as it is reversed by C3 or C5 blockade. Elevated IL-2 in DAF-null contexts persists in memory T cells, highlighting DAF's role in fine-tuning T cell immunity during recall responses. In the context of tumorigenesis, overexpression on cancer cells promotes immune evasion by diminishing . By accelerating decay of C3 convertases, limits C3b/iC3b deposition on tumor surfaces, thereby reducing recognition and engulfment by macrophages and other , as observed in colorectal, breast, and ovarian cancers where high correlates with poor prognosis and resistance to immune clearance. This protective mechanism extends to inhibition of activity, further shielding tumors from innate surveillance.

Disease associations

Paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic stem cell disorder caused by a somatic mutation in the PIGA gene, which encodes a key enzyme in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors. This mutation, occurring in hematopoietic stem cells, results in the absence or severe deficiency of GPI-anchored proteins on the surface of blood cells, including decay-accelerating factor (DAF, or CD55) and membrane inhibitor of reactive lysis (CD59). Without these complement regulators, affected red blood cells, granulocytes, and platelets become highly susceptible to complement-mediated lysis, leading to the hallmark intravascular hemolysis of PNH. The PIGA mutation is X-linked and typically affects a single stem cell clone, which expands over time, with the proportion of PNH-type cells varying among patients. The clinical manifestations of PNH arise primarily from uncontrolled complement activation due to and deficiency. Intravascular is chronic, with paroxysmal exacerbations that were historically termed "nocturnal" because concentrated urine in the morning made more noticeable, though the itself is continuous rather than sleep-specific. This leads to symptoms such as , dyspnea, , and dark urine from . , a major cause of morbidity and mortality, occurs in up to 40% of patients, often in unusual sites like , due to platelet activation and free hemoglobin's procoagulant effects. failure, present in about 30-50% of cases, contributes to cytopenias and may overlap with or myelodysplastic syndromes. PNH has an estimated incidence of 1-2 cases per million individuals annually. Diagnosis of PNH relies on flow cytometry to detect the absence of CD55 and CD59 on peripheral blood cells, particularly granulocytes and monocytes, which provides high sensitivity and specificity for identifying the PNH clone size. Red blood cells are classified into type I (normal GPI expression), type II (partial deficiency), and type III (complete absence), with type III cells predominant in hemolytic PNH. Historical tests like the Ham acid hemolysis test, which demonstrated increased red cell lysis in acidic conditions, have been largely replaced by flow cytometry due to their lower sensitivity and technical demands. Treatment targets complement inhibition and, in select cases, addresses the underlying clonal disorder. , a against complement component C5, blocks the terminal complement pathway, dramatically reducing intravascular , transfusion requirements, and risk in most patients, as shown in pivotal trials. Long-acting C5 inhibitors like offer similar benefits with less frequent dosing. More recently, as of 2025, proximal complement inhibitors such as (approved 2023) and danicopan (approved 2024), which target factor B or factor D to inhibit earlier in the pathway, and crovalimab (approved 2024), a recycling C5 inhibitor, have been approved, providing options for both intravascular and extravascular with oral or . remains a foundational , particularly during . Allogeneic is the only curative option, eradicating the PNH clone and restoring normal hematopoiesis, particularly recommended for young patients with significant failure or refractory disease. Supportive care, including anticoagulation for and iron supplementation for hemoglobinuria-induced losses, complements these approaches.

Complement hyperactivation-associated protein-losing enteropathy (CHAPLE)

Complement hyperactivation-associated protein-losing enteropathy (CHAPLE) is a rare autosomal recessive disorder caused by biallelic loss-of-function mutations in the CD55 gene, leading to deficiency of membrane-bound and resultant hyperactivation of the . First described in 2017, CHAPLE typically presents in early childhood with gastrointestinal symptoms including chronic diarrhea, abdominal pain, and due to intestinal from endothelial damage by uncontrolled complement. Additional features include recurrent infections, angiopathic (e.g., in cerebral or renal vessels), and from , with an estimated prevalence of less than 1 in 1,000,000. Diagnosis involves confirming CD55 mutations, showing absent on blood cells, and evidence of complement hyperactivation (e.g., low C3 levels). Treatment focuses on complement inhibition; pozelimab (Veopoz), a C5 , was approved by the FDA in 2023 as the first specific therapy, administered subcutaneously weekly after an initial intravenous dose, significantly reducing protein loss and risk in clinical trials. Supportive measures include nutritional support, anticoagulation, and infection prophylaxis.

Infectious diseases

Decay-accelerating factor (, also known as CD55) serves as a cellular receptor for several picornaviruses, facilitating their attachment and entry into host cells. Specifically, DAF binds coxsackie B viruses and echoviruses through its complement control protein domains CCP3 and CCP4, which interact with viral proteins to promote . This interaction is critical for infection, as mutations in these domains abolish viral binding. Similarly, certain serotypes of 70 utilize DAF as a primary receptor on ocular and respiratory epithelial cells, enabling and respiratory infections. In , DAF acts as a receptor for merozoites, facilitating their invasion of human erythrocytes; erythrocytes lacking CD55 (e.g., in rare blood group phenotypes) show resistance to infection, highlighting DAF's role in parasite . In the context of human immunodeficiency virus type 1 (HIV-1), DAF contributes to viral evasion of complement-mediated destruction. HIV-1 particles incorporate DAF from infected host cells into their during , where it functions to destabilize C3 and C5 convertases, thereby inhibiting complement opsonization and neutralization in serum. This incorporation enhances viral survival in the bloodstream, as demonstrated by experiments showing reduced complement sensitivity in DAF-associated virions compared to those lacking it. Bacterial pathogens also exploit DAF to modulate host immune responses. interacts with DAF to dampen complement activation, thereby resisting by neutrophils and macrophages. In infection models, DAF provides protective effects for the host against certain streptococcal strains by regulating excessive , although its absence can paradoxically enhance granulocyte-mediated clearance in some cases. Experimental studies using DAF-deficient mice highlight its role in . In models of B3 infection, DAF mice exhibit altered susceptibility to , with reduced severity of cardiac compared to wild-type mice, underscoring DAF's contribution to viral and immune cell activation in the heart.

Clinical and research applications

Therapeutic uses

Recombinant soluble forms of decay-accelerating factor (sDAF) have been investigated as therapeutics to systemically inhibit complement activation and mitigate in complement-related disorders. Preclinical studies demonstrated that sDAF effectively suppresses immune complex-mediated in models resembling by accelerating the decay of C3 and C5 convertases. In , expression of in transgenic pigs has been a key strategy to counteract hyperacute rejection by protecting porcine endothelial cells from complement attack. These genetically modified pigs, incorporating alongside other regulators like and , have extended graft survival in preclinical nonhuman primate models. As of 2025, clinical trials are underway evaluating DAF-expressing gene-edited pig kidneys and hearts for transplantation, with initial procedures demonstrating feasibility and reduced early rejection in end-stage organ failure patients. Cancer therapies targeting DAF leverage its overexpression on tumor cells, which promotes immune evasion by inhibiting complement-mediated lysis. Anti-CD55 monoclonal antibodies enhance antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against DAF-expressing malignancies, such as colorectal tumors. For instance, a novel anti-CD55 antibody activated complement to suppress proliferation, invasion, and migration in colorectal cancer cells, with combination therapy alongside 5-fluorouracil amplifying antitumor effects. The 791Tgp72 antigen, identified as a glycosylated form of CD55, serves as a vaccine target in colorectal, gastric, and ovarian cancers, eliciting T-cell responses and supporting imaging and immunotherapy approaches. In (PNH), where deficiency exacerbates complement-driven , -mimicking strategies complement C5 inhibitors by targeting upstream convertase activity to prevent C3 opsonization and residual extravascular . Proximal inhibitors, such as factor D blockers like danicopan, are combined with C5 inhibitors (e.g., or ) to restore regulation akin to function, improving levels and reducing transfusion needs in patients with incomplete responses to C5 monotherapy. This adjunctive approach addresses the multifaceted complement dysregulation in PNH, enhancing overall disease control.

Pathogen interactions

Research on decay-accelerating factor (DAF, also known as CD55) as a target for interventions has highlighted its role as a cellular receptor exploited by various , enabling strategies to disrupt -host interactions and enhance immune clearance. In antiviral approaches, soluble DAF-Fc fusion proteins have demonstrated efficacy in blocking binding and infection. Specifically, DAF-Fc inhibits B3 (CVB3) infection by competing with cell-surface DAF for viral attachment, reducing plaque formation and across multiple strains. In vivo, administration of DAF-Fc in models of CVB3-induced attenuates in the heart, decreases myocardial , and improves survival rates when given early post-infection, suggesting its potential as a therapeutic trap for enteroviral diseases. These findings have prompted exploration of DAF-targeted receptor traps for development against coxsackieviruses, where soluble forms could neutralize circulating and elicit protective immunity without full . In research, incorporated into virions during budding from infected cells shields the virus from complement-mediated , contributing to immune evasion. Soluble constructs have been investigated to counteract this protection; studies show that -Fc fusion proteins bind to HIV-1 particles, displacing membrane-anchored and restoring susceptibility to antibody-dependent complement-mediated , thereby enhancing viral under complement-sufficient conditions. This approach leverages 's dual role in attachment and complement regulation, potentially amplifying the efficacy of neutralizing antibodies in clearing HIV-infected cells. For bacterial pathogens, DAF serves as an adherence receptor for certain strains, and its diminishes in relevant models. Analogous mechanisms apply to like diffusely adhering (DAEC), which use Afa/Dr adhesins to bind DAF on epithelial cells, facilitating colonization and invasion. In vitro of DAF with monoclonal antibodies significantly reduces DAEC adherence to host cells, inhibiting formation and bacterial internalization. Emerging investigations into DAF's involvement in reveal its upregulation in severe cases, correlating with dysregulated complement activation and poor outcomes. In patients with severe infection, CD55 expression is elevated on monocytes, + T cells, and + T cells, suppressing type I responses and promoting excessive via unchecked complement deposition. hijacks host CD55 for incorporation into virions, impairing antibody-dependent complement-mediated and exacerbating endothelial damage and . Therapeutic targeting of upregulated DAF, such as through monoclonal antibodies or soluble inhibitors, restores complement sensitivity , suggesting potential interventions to mitigate in critical by enhancing viral clearance and reducing hyperinflammation.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC5833118/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2327052/
  3. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/decay-accelerating-factor
  4. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-cd55-deficient-protein-losing-enteropathy-chaple-disease
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC124913/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC128121/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC153622/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC4868954/
  9. https://www.sciencedirect.com/science/article/pii/S0021925820879010
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC4727430/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC2115511/
  12. https://pubmed.ncbi.nlm.nih.gov/2477368/
  13. https://www.omim.org/entry/125240
  14. https://www.ncbi.nlm.nih.gov/gene/1604
  15. https://doi.org/10.1016/j.ygeno.2006.01.006
  16. https://www.ensembl.org/id/ENSG00000196352
  17. https://www.omim.org/entry/613793
  18. https://pubmed.ncbi.nlm.nih.gov/7519480
  19. https://pubmed.ncbi.nlm.nih.gov/10211099/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC1905706/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC11031091/
  22. https://www.sinobiological.com/research/complement-system/daf
  23. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1617140/full
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC2867804/
  25. https://www.researchgate.net/publication/21873193_Expression_of_the_DAF_CD55_and_CD59_antigens_during_normal_hematopoietic_cell_differentiation
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC9889927/
  27. https://rupress.org/jem/article/165/3/848/49843/Identification-of-the-complement-decay
  28. https://pubmed.ncbi.nlm.nih.gov/17182573/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC6536589/
  30. https://pubmed.ncbi.nlm.nih.gov/8824468/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC539416/
  32. https://www.nature.com/articles/3780441
  33. https://doi.org/10.4049/jimmunol.177.2.1070
  34. https://doi.org/10.3389/fimmu.2023.1290684
  35. https://doi.org/10.1084/jem.20040863
  36. https://doi.org/10.3389/fimmu.2019.01074
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC4695989/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC2721357/
  39. https://www.ncbi.nlm.nih.gov/books/NBK562292/
  40. https://ashpublications.org/blood/article/108/11/985/130184/The-Incidence-and-Prevalence-of-Paroxysmal
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC5640555/
  42. https://www.nejm.org/doi/full/10.1056/NEJMoa061648
  43. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-iptacopan-paroxysmal-nocturnal-hemoglobinuria
  44. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-danicopan-add-on-therapy-adults-paroxysmal-nocturnal-hemoglobinuria
  45. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-crovalimab-akkz-paroxysmal-nocturnal-hemoglobinuria
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC2878778/
  47. https://www.nejm.org/doi/full/10.1056/NEJMoa1615887
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC6690356/
  49. https://www.orpha.net/en/disease/detail/566175
  50. https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2388267
  51. https://pubmed.ncbi.nlm.nih.gov/10608785/
  52. https://journals.asm.org/doi/pdf/10.1128/iai.72.8.4859-4863.2004
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC190469/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC4465434/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC2192116/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC2838113/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC3184942/
  58. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0024431
  59. https://pubmed.ncbi.nlm.nih.gov/16817758/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC2956018/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC1906445/
  62. https://pubmed.ncbi.nlm.nih.gov/1380537/
  63. https://www.sciencedirect.com/science/article/abs/pii/S016231099700057X
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC12037586/
  65. https://nyulangone.org/news/first-gene-edited-pig-kidney-transplant-clinical-trial-begins-nyu-langone-health
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC11788277/
  67. https://pubmed.ncbi.nlm.nih.gov/31578581/
  68. https://www.spandidos-publications.com/or/42/6/2686
  69. https://aacrjournals.org/cancerres/article/59/10/2282/505081/Decay-Accelerating-Factor-CD55-A-Target-for-Cancer
  70. https://www.dovepress.com/advances-in-complement-inhibition-therapies-for-paroxysmal-nocturnal-h-peer-reviewed-fulltext-article-JBM
  71. https://onlinelibrary.wiley.com/doi/10.1002/ajh.26882
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC12572029/
  73. https://journals.asm.org/doi/10.1128/jvi.79.18.12016-12024.2005
  74. https://pubmed.ncbi.nlm.nih.gov/15073680/
  75. https://www.sciencedirect.com/science/article/pii/S0023683722035954
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC3224960/
  77. https://www.sciencedirect.com/science/article/abs/pii/S0165247804003128
  78. https://www.pnas.org/doi/10.1073/pnas.032668099
  79. https://www.biorxiv.org/content/10.1101/2022.10.07.510750v1.full-text
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC11520101/
  81. https://www.tandfonline.com/doi/full/10.1080/22221751.2024.2417868
Add your contribution
Related Hubs
User Avatar
No comments yet.